Current Concepts in Androgen Deprivation Therapy.
10.5124/jkma.2004.47.5.408
- Author:
Jeong Hee HONG
1
;
Han Yong CHOI
Author Information
1. Department of Urology, Sungkyunkwan University School of Medicine, Samsung Seoul Medical Center, Korea. hjh178@freechal.com, hychoi@smc.samsung.co.kr
- Publication Type:Original Article
- Keywords:
Prostate cancer;
Castration;
Androgen antagonists
- MeSH:
Androgen Antagonists;
Castration;
Gonadotropin-Releasing Hormone;
Orchiectomy;
Prostatic Neoplasms;
Testosterone
- From:Journal of the Korean Medical Association
2004;47(5):408-416
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The hormonal sensitivity of prostate cancer has been exploited clinically since Huggins and Hodges established the suppressive effects of castration on prostate cancer. Despite over sixty years of research into alternate modalities, androgen deprivation therapy (ADT) has become the mainstay treatment for locally advanced and metastatic prostate cancer. Suppression of testosterone production, the primary goal of hormonal therapy, can be achieved by a multitude of treatments. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, luteinizing hormone-releasing hormone (LHRH) analogues or complete androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity. This article provides an overview of the hormonal therapies currently used in advanced prostate cancer.
